Active surveillance for favorable and intermediate risk prostate cancer (PRIAS-JAPAN)
Not Applicable
Recruiting
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000048095
- Lead Sponsor
- Kagawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 1900
Inclusion Criteria
Not provided
Exclusion Criteria
1) Men who can not or do not want to be radiated or operated. 2) A former therapy for prostate cancer. 3) For patients with a life expectancy <10yrs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method metastasis-free survival
- Secondary Outcome Measures
Name Time Method cancer-specific survival, the rate of reclassification, continuation rate of active surveillance, Quality Of Life(QOL)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are associated with favorable/intermediate risk prostate cancer progression during active surveillance in PRIAS-JAPAN?
How does active surveillance in PRIAS-JAPAN compare to radical prostatectomy in terms of biochemical recurrence rates for intermediate risk prostate cancer?
Which genomic or proteomic signatures predict response to active surveillance versus immediate treatment in PRIAS-JAPAN's prostate cancer cohort?
What are the long-term adverse event profiles of active surveillance versus external beam radiotherapy in Japanese prostate cancer patients?
Are there combination strategies involving biomarker-guided active surveillance and novel therapies being explored in Kagawa University's prostate cancer trials?